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ABSTRACT 
The Development of a Model of Alpha Helix Formation 
for Transmembrane Peptides. (April 2000) 
Geoffrey Alexander Funk 
Department of Biochemistry dr Biophysics 
Texas AdrM University 
Fellows Advisor: Dr. J. Martin Scholtz 
Department of Biochemistry Ec. Biophysics I 
Department of Medical Biochemistry 4 Genetics 
Researchers have studied the folding and binding properties of peptides in water 
for many years, but only recently has anyone attempted to explore those same tendencies 
in an environment similar to that of a transmembrane protein incorporated into the 
phospholipid bilayer of the cell. To this end, we have been working on the synthesis of a 
group of peptides with the general sequence 'HsN-Alaz-Lens-Ala7-Ttp-Ala-X-Alatc- 
Lyss-COOH, where we will substitute all twenty naturally occurring amino acids into 
position X. We have successfully synthesized and purified the peptide in which the 
guest position X is filled by an isoleucine — due to the difficulty of the sequence 
involved, we have been unable to synthesize and purify eighteen of the remaining 
nineteen. Peptides, once synthesized, are characterized by MALDI mass spectrometry 
and HPLC and purified peptides are studied using circular dichroism (CD) spectroscopy 
to determine the ot-helicity. Initial results suggest that the transmembrane environment 
will indeed alter the propensities of the various amino acid residues to form ct-helices, 
though to what degree still remains to be seen. Once complete, this study should make it 
possible to determine a system for predicting tr-helix formation in membrane proteins 
and determine the basic rules that guide such helix formation, 
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INTRODUCTION 
Studies in recent years have shown that the propensity of certain residues to form 
ot-helices or P-sheets is altered from their tendencies in water when studied in membrane 
proteins. Residues that lend themselves to one type of secondary structure can reverse 
these inclinations from water to a lipid bilayer according to Li and Deber (1994) and 
thus lend no data when studying an environment similar to that which would normally 
be found. As such, while large amounts of data have been compiled, these data do not 
necessarily lend themselves to practical applications. A different approach to the 
problem is necessary to answer some of the questions in this much-researched area of 
biochemistry. 
To this end, I have helped to begin the work to develop a model of ot-helix 
stability in a membrane environment similar to that of the cell. By studying a series of 
synthetic peptides using techniques such as circular dichroism spectropolarimetry (CD) 
and fluorescence and modifldng a single guest residue position between the various 
peptides, it should be possible to determine a model of the propensity of various residues 
to form ot-helices while situated in the bilayer. 
This thesis follows the style and format of Analytical Biochemistry. 
The peptide we have been developing is a 31-residue peptide with the sequence 
'HsN-A)az-Leus-Ala&-Trp-Ala-X-Alats-Lyss-COOH, a peptide similar to that used by 
Liu and Deber (1997) in some of their work. This sequence is particularly well suited to 
the task for a number of reasons: 
1) The highly polar poly-Lys at the N-terminus of the peptide provides a 
terminal portion of the peptide that will orient itself into the extra-lipid and 
polar environment, thus favoring a transmembrane orientation. 
2) Conversely, the highly hydrophobic poly-Ala and poly-Leu stretches should 
cause the majority of the peptide to bury itself within the hydrophobic lipid 
layer, similarly favoring a transmembrane orientation. 
3) The guest residue position, the X-site, is in a central location within the 
peptide. This will decrease the possibility that the polar environment around 
the lipid layer will affect the secondary structural tendencies of the guest 
residue. 
4) The centrally located Trp absorbs ultraviolet light at a wavelength of 275nm, 
allowing for easier purification using the techniques of HPLC and FPLC, as 
well as opening up the possibility for fluorescence studies when that phase of 
this project is reached. 
5) Alanine and leucine both have high ot-helix forming propensities in water- 
based studies. With such a high concentration of these residues in the 
peptide, we can be quite certain that the peptide will show high helical 
content in our initial non-membrane-associated CD work. 
6) The peptide is also long enough that it should be able to fold effectively and 
extend across the membrane so that a transmembrane configuration may be 
more favorable than a surface configuration. 
Thus, this peptide should be able to meet all of the necessary requirements for the 
studies we are attempting to perform. 
The lipid membrane may consists of any standard phospholipid so long as the 
phase transition temperature of the lipid is low enough that we do not have to worry 
about whether or not the lipid is undergoing phase transition and possibly leaving the 
liquid phase. If this were to happen, we would be unable to determine whether or not 
any data that we might acquire was the result of the crystalline phase or the actual 
transmembrane peptide in the appropriate configuration in the liquid phase. 
The important feature of the lipid membrane is that of thickness — as mentioned 
earlier, if the peptide extends too far beyond the membrane after folding (too long), there 
is a good chance that a transmembrane configuration would force the hydrophobic core 
of the peptide into the polar extra-membrane solvent. Conversely, if the peptide folds 
such that it cannot extend across the entire membrane (too short), the hydrophilic termini 
of the transmembrane peptide will be exposed to the hydrophobic interior of the lipid 
bilayer. Figure 1 demonstrates these concepts: 
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Figure 1; Tendencies for peptide orientation as a result of membrane thickness. In a) the folded peptide 
extends such that only the hydrophilic regions (black) of the peptide are exposed to the polar exterior 
environment, while the hydrophobic regions (gray) reside solely in the non-polar interior of the bilayer. In 
b) the bilayer is too thin, causing exposure of the hydrophobic peptide core to the polar environment 
outside the bilayer; in this situation, a surface configuration may be favorable. Likewise, in c) the 
membrane is too thick, causing the hydrophilic termini of the peptide to be exposed to the hydrophobic 
bilayer core, resulting in a surface configuration. 
In either of these situations, such exposure is highly unfavorable — as a result, the more 
favorable surface configuration for the peptide would most likely be favored. This is not 
to say that there will be no instances of the transmembrane configuration, but instead 
that it is disfavored in comparison to the surface orientation. 
BACKGROUND 
Many years of study have gone into the propensity of various amino acid 
residues to form n-helices in water. In such an environment it is now possible both to 
predict the n-helical propensity of a given sequence and to design a specific sequence so 
as to induce helix formation. Little attention, however, had been paid to the realm of 
membrane proteins and helix formation in such a hydrophobic environment until recent 
years. 
No definite mechanism has been provided for the integration of transmembrane 
proteins into membranes, but it is known that n-helices are extremely good structures in 
such proteins. This is due to the intrinsic ability of the n-helix to bury the polar 
backbone groups from the hydrophobic environment of the lipid bilayer. The data 
regarding the n-helix propensity of the various residues in water, however, do not lend 
themselves to solid conclusions about the same propensity in a lipid bilayer (Li and 
Deber, 1994). Thus, a definitive model needs to be developed for membrane proteins. 
As we desire to isolate and study membrane proteins, it will be important to 
maintain the transmembrane configuration of the proteins. Liu and Deber (1997) 
demonstrated that the length of the folded peptide and the fluidity of the bilayer have 
effects on the conformation of the protein in relation to the bilayer. With thin layers, 
addition of decane (incorporated into the center of the membrane) or cholesterol leads to 
an increase in the number of peptides in the transmembrane configuration, while in thick 
layers such addition drives the proteins to the surface configuration. This can lead to 
effective isolation of either configuration, but will more profoundly affect my studies in 
the section of transmembrane peptides. 
SPECIFIC AIMS 
As was mentioned prior to the start of this project, we were aware that the scope 
of the project was quite large and it was unlikely that the work would be completed 
within the time allotted. Still, any progress that could be made would be worth the effort 
and would hasten the completion of the work. From the outset, the following goals were 
set forth: 
2) 
3) 
4) 
Synthesize the transmembrane peptides with each of the twenty amino 
acids substituted in at the guest position. 
Conduct preliminary studies using CD and fluorescence 
spectroscopies in water to confirm the helical propensity of the 
peptides. In addition, studies in non-polar solvents, such as methanol, 
would be completed at this time. 
Determine a refined technique for inserting the peptide into vesicles 
and for isolating the transmembrane configuration by altering bilayer 
width and fluidity. 
Perform similar CD and fluorescence studies with the various forms of 
the transmembrane peptide. 
Begin to formulate hypotheses on helical propensity in membranes. 
MATERIALS AND METHODS 
Peptide Synthesis: 
Peptide synthesis was attempted using three different methods: 1) automated 
Fmoc solid phase chemistry; 2) automated FastMoc solid phase chemistry; and 3) 
FastMoc solid phase chemistry by hand. 
Automated syntheses were carried out on an Applied Biosystems 43 IA Peptide 
Synthesizer either by continuous-flow Fmoc or FastMoc solid phase chemistry. In either 
method, peptides were synthesized upon Rink resin, activation of the amino acid 
residues occurs using N-methylpyrrolidone (NMP) and I-hydroxybenzotriazole (HOBt), 
and coupling uses Fmoc-protected amino acids. The notable difference between Fmoc 
and FastMoc chemistry involves the use of 2-(IH-benzotriazol-l-yl)-1, 1, 3, 3- 
tetramethyluronium hexafluorophosphate (HBTU) in the HOBt/NMP activation, as well 
as in situ activation by diisopropylethylamine (DIEA), in FastMoc chemistry, resulting 
in higher efficiency and shorter coupling times. 
Hand syntheses of peptides were carried out using the same FastMoc solid phase 
chemistry as discussed above, though coupling times and reagent concentrations 
(specifically molar ratios of amino acid: desired synthesis scale) were increased in the 
hopes of increasing coupling efficiency and synthesis accuracy further. A 0. 03 mmol 
reaction scale was used (in terms of resin volume). The following method table 
highlights the three reactions of the hand synthesis: 
TABLE 1 Non-automated chemical synthesis of peptides 
Reaction Reagents Reaction Time 
Deprotection 
Coupling 
Capping 
— 20% Piperidine 
in NMP with 1% Triton X-100 
— 40 molar excess of desired amino 
acid residue 
- 552 mg HOBt 
- 1365 mg HBTU 
- 1. 260 mL DIEA 
in NMP with 1% Triton X-100 
- 5% Pyridine 
- 5% Acetic anhydride 
in NMP with 1% Triton X-100 
5 minutes, flip stack, 5 
minutes 
2-6 hours 
15 minutes, flip stack, 15 
minutes 
This series of three reactions is repeated for every residue of the peptide. Cleavage from the resin occurs 
after the final capping reaction. 
After each reaction, all samples undergo five consecutive washes in NMP with 
1% Triton X-100 in order to remove any remaining reagents before beginning the next 
reaction. 
Cleavage of the peptide from the resin involves two hours in a gyrorotary bath 
with an adequate volume of trifluoroacetic acid (TFA) I scavenger solution (5% anisole, 
95% TFA), followed by extraction with approximately 40 mL cold tert-butyl methyl 
ether and lyophilization. 
Peptide Purification: 
Initially, peptide purifications were carried out on a reverse-phase LCC-500 
PLUS from Pharmacia with a SpectraSERIES UV I 00 from Thermo Separation Products 
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and FPLCdirector software using an acetonitrile gradient in 0. 1% TFA. Later 
purifications were carried out on the Pharmacia AKTA HPLC unit with a Waters 25mm 
column and the Unicorn software program, again using an acetonitrile gradient in 0. 1% 
TFA. Fractions were collected according to absorbance at 275nm (absorbance 
maximum of Trp) for FPLC and at 275nm, 254nm, and 225nm for HPLC. To determine 
purity of peptides, reverse-phase FPLC, HPLC, and MALDI-TOF mass spectrometry 
using a Perspectives Voyager mass spectrometer were used. 
Phospholipid Vesicles: 
Peptide incorporation used a solution of the peptide in chloroform/methanol (2: I) 
and mixed with the lipid dioleoylphosphatidylcholine (DOPC) in the same solvent at a 
ratio of 1 mole peptide: 100 moles lipid. The solution is then evaporated under nitrogen 
using a RotoVap system, thereby creating a lipid film covering the surface of its 
container. This lipid film must then be rehydrated for 30 minutes in 10 mM Tris-HC1 
buffer, 10 mM NaCI, pH 7. 0, with vortexing. After rehydration the lipids are sonicated 
on ice using a bath sonicator made by Laboratory Supplies Co. , Inc. , until the solution 
moves from an opaque white to a slightly more translucent bluish-white. The final 
concentration of the mixture should be 30 ltM for CD studies and 4 AM for fluorescence 
spectroscopy. 
Circular Dichroism Measurements: 
CD spectra were recorded using an Aviv 62DS CD spectrapolarimeter using 1 
cm quartz cuvettes at room temperature. Helicity was measured by observing the 
characteristic minima at 222nm and 208 nm in wavelength scans. The final specna are 
analyzed with a number of available programs to determine n-helical content. 
Measurements were carried out in both polar and non-polar solvents in order to 
determine differences in peptide behavior between the two environments. 
Cloning: 
Cloning attempts were made using the pZH3 plasmid vector containing 
ampicillin resistance. Sequential restriction digests at the SalI and BamHI sites were 
carried out to remove a 2 kb stuffer fragment, after which a 123-base fragment 
containing appropriate codons for our peptide and the restriction sites for BamHI and 
SalI was restricted and then ligated into the cleaved plasmid. The sequence of that 123- 
base fragment is contained in Figure 2: 
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DNA 5' — GCT GCT CTG CTC CTG GCT GCT GCT GCT GCT 
Peptide 'H, N — Ala Ala Leu Leu Leu Ala Ala Ala Ala Ala 
GCT GOT TGG GCT GOT GOT GCT GCT GCT GCT GCT 
Ala Ala Trp Ala Ala Ala Ala Ala Ala Ala Ala 
GCT GCT GCT GCT AAA AAG AAA AAG AAG AAA - 3' 
Ala Ala Ala Ala L s L s L s L L s L - COOH 
Figure 2: Coding sequence for transmembrane peptide insert and corresponding amino acid residues. The 
above DNA sequence corresponds to the desired DNA fragment to be inserted into the pZH3 piasmid. 
The template strand corresponding to the above coding sequence was ordered from integrated DNA 
Technologtes, Inc. 
Transformations took place using electroporation and heat shock methods into a 
competent E. coif cell line. Transformed cells were plated on Luria broth (LB) agar 
plates containing ampicillin and allowed to grow for 24 hours. Any colonies found after 
24 hours were transferred into test tubes containing a small volume of LB and growth- 
prohibitive concentrations of ampicillin and allowed to grow for a further 24 hours. 
Aliquots of these preparations were then purified using the Qiagen DNA mini-prep kits 
and subjected to SalI and BamHI restriction digests. Agarose gel electrophoresis (1. 2% 
agarose gels) was used after each digestion in this process to determine the presence or 
absence of appropriate sized fragments. Appropriate bands were purified from the 
agarose gel and used for further restrictions or ligations. 
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DISCUSSION AND RESULTS 
Peptide Synthesis by Chemical Means: 
To date, we have been able to synthesize and purify the isoleucine variant of our 
target sequence successfully. Some initial CD work has been done and will be discussed 
later. We may also have been able to synthesize a second variant, though that has yet to 
be confirmed. As such, we are currently attempting to chemically synthesize the peptide 
by hand (not using the automated synthesizer) and also to use a modified cloning 
procedure, the latter being undertaken by Jason Schmittschmitt, one of the graduate. 
students in the lab. 
The majority of our attempts to synthesize the peptides were made using the 
automated peptide synthesizer and Fmoc chemistry — unfortunately this method ran into 
a recurring problem in that the product of these syntheses was only -80% pure, the rest 
of the product being of slightly lower mass when mass spectrometry was used to analyze 
the results of the synthesis. Calculations led to the determination that this impurity peak 
was a form of the peptide missing one alanine residue (AAIa) but otherwise intact. 
Repeated attempts to purify using both FPLC and HPLC were unsuccessful in 
eliminating the impurity — both the transmembrane peptide and the AAla version came 
off the chromatography column at the same time and were inseparable by our 
techniques. With such a large impurity, any analytical data obtained is dubious. If there 
were a way to determine which alanine had been lost, it may have been possible to use 
ihis new sequence to create the rest of the peptides. With twenty alanine positions 
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involved, however, it is not possible to determine the exact sequence of the M. la 
peptide. 
It is highly likely that the large hydrophobic content of this peptide is the very 
problem causing the synthesis difficulties. With up to a possible twenty-four 
hydrophobic residues (20 Ala, 3 Leu, and 1 at the X-position), this peptide is probably 
attempting to bury as many of the hydrophobic residues as possible before synthesis is 
even complete. The peptide is also quite long for synthesis: 20-mers and below are not 
uncommon for lab synthesis, but as the desired peptide gets longer, the efficiency of the 
syntheses generally go down. 
This is a result of a number of factors — first, of course, the length of the peptide; 
second, the proximity of the active sites upon the resin bead on which the peptide is 
built; and third, the secondary structural characteristics of the sequence itself, to name a 
few. In combination, these can create an environment in which long syntheses become 
extremely difficult. If there is not an adequate distance between the active sites on the 
resin beads, it becomes possible for the highly hydrophobic regions of the 
transmembrane peptide to favor burying those hydrophobic regions by either 
aggregation of a number of strands of the growing peptide or simply by folding back 
upon itself. Either of these, one can reason easily, will result in a decrease in the 
coupling efficiencies — as a result, it is not unthinkable that a single coupling will not 
succeed in a number of strands. 
This suggests several solutions that are now being incorporated into the current 
synthesis efforts or may be used in future efforts: 1) increase length of time given for 
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coupling reactions, thereby increasing the likelihood of even unfavorable couplings; 2) 
increase the concentrations of the activated amino acid residues, again increasing the 
chances of coupling through brute force; 3) use a detergent to decrease favorable 
secondary structure folding during synthesis and thus leave the ends of the peptides in 
consnuction more accessible for successful coupling reactions rather than being buried 
in some form of self- or inter-chain aggregates; and 4) use a resin with an increased 
distance between active sites to decrease the chance of interchain dimer- or 
oligomerization (though this would not have an effect if the problem is one of secondary 
structure during synthesis). 
Due to problems with the apparatus itself, we have not been able to complete a 
FastMoc automated synthesis successfully, though the higher coupling efficiency 
associated with this chemistry led us to attempt FastMoc hand synthesis. This pursuit, 
due to a shortage of NMP, will not be completed prior to the submission of this thesis, 
though we should have indications as to whether or not chemical synthesis could be 
successful shortly. Of the possible solutions discussed above, we are incorporating the 
use of a detergent (1% Triton X-100) and increasing coupling times and amino acid: 
resin ratios. 
That it is possible to generate this peptide via automated chemical synthesis is 
not in doubt — mass spectrometry and liquid chromatography have confirmed that the 
isoleucine variant of the transmembrane peptide is of the correct mass and is extremely 
pure. This may not be the most efficient way to produce the peptides, however, as the 
final yield full-length peptide is rarely so high or so pure as in the case of the isoleucine 
variant. As such, it is still very important to pursue other approaches in order to 
optimize the production of the peptides. 
Peptide Synthesis Using Molecular Genetics: 
While initial results using a cloning approach for the synthesis of the peptide 
were not entirely promising, a current attempt headed by graduate student Jason 
Schmittschmitt seems to suggest that it may indeed be possible to create this peptide by 
creating a plasmid containing the coding sequence for the transmembrane peptide and 
using E. coli cells to mass-produce it. This work is also currently in progress and should 
be advanced enough to determine whether not this is a viable solution to the problem in 
the near future. 
Initial attempts to clone the peptide into a vector used the pZH3 plasmid from Dr, 
Hu* s lab in the Department of Biochemistry and Biophysics — this plasmid had an easily 
removed "stuffer" sequence of about 2 kb that could easily be cleaved with restriction 
enzymes. After purification to remove the Zkb stuffer fragment, it should have been 
possible to ligate our template fragment into the plasmid. For some reason, however, 
this never seems to have occurred successfully. We were able to obtain growth on 
ampicillin-resistant media of E. coli carrying the vector, but we were unable to 
successfully isolate our insert when analyzing the DNA-purification product from those 
cells. Sequencing also became a problem, though we attempted it on several different 
occasions in several different sequencing labs — the fragment we submitted seemed to 
aggregate, thereby making sequencing impossible. 
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Current results suggest that the problem we initially encountered was indeed 
during insertion of the transmembrane peptide coding sequence into the vector. Using a 
commercial kit expressly for the purpose of enhancing the ligation efficiency of low- 
yield insertions such as this, we have now been able to clone the transmembrane peptide 
sequence into a high-efficiency ligation vector successfully. After successful sequencing 
of the necessary region of the plasmid, we will then continue to isolate this plasmid after 
amplification and isolate our insert in high yield. This will allow us to then use this 
high-yield product to increase the likelihood of a successful insertion into the pZH3 
plasmid. 
Assuming successful insertion into pZH3 and assuming successful amplification, 
it should be possible to isolate the transmembrane peptide product by using an ion- 
exchange column to separate the peptide out based on the histidine-tag that is added to 
the peptide as a result of the plasmid. While this will add another residue to the length 
of the peptide, its effect on folding should not be too worrisome. If it is possible to 
progress to this stage with the cloning approach, it is highly likely that synthesis of the 
rest of the transmembrane peptides will follow shortly thereafter by using site-directed 
mutagenesis on the original vector. 
This method of peptide synthesis may prove successful by the end of this 
semester, though more work has to be done. 
18 
Creation of Small Unilamellar Vesicles: 
Various techniques were studied to determine the best method of creating 
unilamellar vesicles for our experiments. Key to our studies are homogeneity of the 
vesicles produced and small enough vesicles that interference with CD spectra is 
minimized to regions below approximately 200 nm. To this end, we attempted to use 
two different extrusion techniques, as well as both probe and bath sonication. 
Extrusion methods, involving the repeated passage of the lipid sample through a 
membrane or small opening, yielded mixed results. A hand-held device developed by 
Avestin was tested but did not seem to produce the required vesicle size — the pores in 
the membrane through which the lipid was passed were far too large (50 nm in 
diameter), resulting in significant light scattering during CD experiments. A second 
procedure using a French pressure cell was also tested, but indications from a BioRad 
Bio-Gel A size exclusion column indicated that these were also far too large and not as 
homogeneous as desired. 
Probe sonication was discarded relatively quickly due to the introduction of fine 
metallic particles from the sonicating probe. While centrifugation can remove these 
particles relatively easily, we moved onto bath sonication as it seemed to achieve similar 
results without the added step. At the time of the probe sonication experiments, we were 
also using dimyristoylphosphatidylcholine (DMPC) as our lipid of choice and it was 
difficult, if not impossible, to keep the lipid above its phase transition temperature while 
at the same time keeping the probe on ice so as not to overheat the instrument. 
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Bath sonication has proven the most effective method in terms of both 
homogeneity of vesicle size qualitatively and in terms of decreasing CD light-scattering 
problems. Size exclusion experiments of this product indicated one peak (studying 
absorbance at 254 nm) of relatively small vesicles, and CD scattering appeared at 
approximately 200 nm and shorter wavelengths but it did not interfere at wavelengths 
greater than 205 nm needed to characterize ct-helical structure. 
As noted earlier, original experiments were conducted using DMPC, with a phase 
transition temperature at approximately 23'C. We later chose to switch to 
dioleoylphosphatidylcholine (DOPC), as its phase transition occurred at — 22'C, allowing 
us to discount such transitions as a source of difficulty. 
Studies involving peptide orientation and cholesterol/decane addition were not 
performed at the time of writing, though this will certainly be one of the next steps in the 
vesicular studies. Also, electron microscopic techniques have generally been employed 
by other researchers in this area to determine accurately both size and homogeneity of 
vesicles produced for transmembrane studies — this too will need to be done in the near 
future. Currently, however, optimization of peptide synthesis remains the highest 
priority. 
Isoleucine Variant of the Transmembrane Model Peptide: 
The isoleucine variant of the transmembrane model peptide, with the sequence 
'H&N-Ala&-Leu&-Ala7-Trp-Ala-lie-AlaI&&-Lyss-COOH, was successfully synthesized 
using the Applied Biosystems 431A Peptide Synthesizer and purified using the 
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Pharmacia AKTA HPLC unit with a Waters 25mm column. As with all other automated 
syntheses, initial mass spectrometry experiments indicated a ala impurity qualitatively 
estimated at approximately 15% of the final product. In this case, however — using the 
standard acetonitrile gradient in water with 0. 1% TFA — the peaks representing the AAIa 
form and the full-length transmembrane model peptide were disparate enough that 
separation was possible. Further mass spectrometry indicated a single peak at a mass of 
approximately 2817, corresponding to the isoleucine variant of the transmembrane 
model peptide. Figure 3 contains the mass spectrum corresponding to that purification, 
obtained from the Perspectives Voyager mass spectrometer: 
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Figure 3: Mass spectrum t'rom the isoleucine of the transmembrane model peptide. Purification was 
performed using the Pharmacia AKTA HPLC and an acetonitrile gradient with 1% TFA. Note the 
absence of any peak corresponding to a AAla form, which would have fallen at approximately 2747 mass 
units. 
CD studies were performed of that purified peptide at concentrations of 1mM, 
SmM, and 10mM in polar and non-polar environments — water and methanol, 
respectively, This allowed us to determine that the peptide was indeed helical in both 
environments. CD spectra corresponding to such data follow in Figures 4 and 5. 
Definitive evidence that the peptide is indeed helical allows us to continue on with 
experimentation — we know that our current sequence will indeed form a helix in order 
to bury the hydrophilic backbone of the transmembrane sequence and will thus allow us 
to use the transmembrane model peptides, once synthesized, to mimic natural 
transmembrane helices in order to determine the contributions of the various amino acids 
to secondary structure. 
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CD Study of Transmembr ane Pepttde- 
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Figure 4: CD spectra of the transmemhrane model peptide at three different concentrations in water. 
Characteristic minima at 208 and 222 nm in circular dichroism experiments are associated with ot-hclicat 
conformation of the analyte. 
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Figurc 5: CD spectra of the transmembrane model peptide at three different concentrations in methanol. 
Characteristic minima at 208 and 222 nm in circular dichroism cxperimenms are associated with a-helical 
conformation of the analyte. 
Also of interest is the differing response to the change of peptide concentration as seen 
in Figures 4 and 5, Note that in water the peptide's ellipticity increases as concentration 
increases, but the exact opposite is true for the methanol study. Little can be said 
regarding this data, but it is possible that the differing effects of concentration may be 
the result of the solvent in which the peptide is dissolved. This hints at some of the 
interesting discoveries that may be made regarding transmembrane proteins and helical 
propensities as our studies continue. 
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CONCLUSIONS 
We have been able to demonstrate that the synthesis of the transmembrane model 
peptide is possible chemically, though the low efficiency suggests that there is probably 
a better method for its production. As such, work will continue on both chemical and 
molecular genetic approaches to enhance the yield and purity of the peptide so that the 
synthesis of the rest of the transmembrane model peptides will be far easier than this first 
one. Almost from the outset, we were aware that this would be a difficult sequence with 
which to work, so the relative lack of success in actual synthesis is mitigated by the fact 
that we were able to successfully complete at least one peptide, demonstrating that the 
transmembrane sequence as delineated earlier can be synthesized and is a viable 
sequence to study for our helical propensity study. 
Initial CD data are also encouraging — the isoleucine variant of the 
transmembrane model peptide is indeed helical in both polar and non-polar 
environments. CD studies have yet to be performed with the transmembrane peptide 
inserted in the lipid vesicles, but the fact that the peptide is highly helical in these initial 
studies is very encouraging for later work. Now it only remains to be seen the 
differences between the transmembrane peptide variants to start determining differences 
in helical propensity among the twenty naturally occurring amino acids. These studies 
will be conducted in polar and non-polar solvents initially, as with the transmembrane 
model peptide isoleucine variant, and then proceed on to the vesicle-integrated level. 
25 
Vesicular work to this point has also been quite encouraging. As soon as the rest 
of the peptides are synthesized, work can be completed to determine the optimum 
vesicular preparation for our peptide and also whether or not the addition of a long-chain 
hydrocarbon will be necessary for the transmembrane model peptide to insert 
appropriately in the nansmembrane configuration. Fluorescence work will be used to 
confirm these orientations using methods similar to those performed by Li and Deber 
(1997). 
There is still a great deal of work to be done — this project was never intended to 
be completed in the short time available through the University Undergraduate Research 
Fellows program. But the groundwork has been laid so that soon it will be possible to 
finish the synthesis and purification of the transmembrane model peptide variants and 
begin the full-fledged effort to determine a helical propensity scale in transmembrane 
environments based on the data from the transmembrane model peptide experiments. 
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